Search
                    Carboplatin Treatment Options in Illinois
A collection of 531 research studies where Carboplatin is the interventional treatment. These studies are located in the Illinois, United States. Carboplatin is used for conditions such as Non-Small Cell Lung Cancer, Ovarian Cancer and Lung Cancer.
            505 - 516 of 531
        Featured Trial
                
                Healthy Participants Needed (Colonoscopy + Cancer Screening)
            
        Recruiting
            
        Earn $325 - $475 in electronic payment card compensation for your time and effort by participating in a clinical study to develop a blood test that may one day help screen for colon cancer. Take a quick quiz to see if you qualify.
    
    
                            Conditions: 
                                    
        
            
                        Healthy
                    
                                    
                        Healthy Volunteers
                    
                                    
                        Healthy Subjects
                    
                                    
                        Healthy Volunteer
                    
                                    
                        Healthy Participants
                    
                                    Featured Offer
                
                Lose Weight with GLP-1 Medications
            
        Recruiting
            
        Policy Lab has partnered with OnlineSemaglutide.org to offer trusted access to semaglutide and other GLP-1 medications, including generic alternatives to Ozempic® and Wegovy®. 
GLP-1 medications are scientifically backed to help individuals achieve significant weight loss—on average, 15-20% of body weight within a year.
As a valued user, you’re eligible for $50 off your first program with code policy-lab-50.
    GLP-1 medications are scientifically backed to help individuals achieve significant weight loss—on average, 15-20% of body weight within a year.
As a valued user, you’re eligible for $50 off your first program with code policy-lab-50.
                            Conditions: 
                                    
        
            
                        Overweight
                    
                                    
                        Overweight and Obesity
                    
                                    
                        Obesity
                    
                                    
                        Weight Loss
                    
                                    
                        Morbid Obesity
                    
                                    Featured Trial
                
                Stroke Clinical Study
            
        Recruiting
            
        A clinical study for people that suffer with Stroke
    
    
                            Conditions: 
                                    
        
            
                        Stroke
                    
                                    Featured Trial
                
                Chronic Kidney Disease (CKD) Clinical Study
            
        Recruiting
            
        A clinical study for people that suffer with Chronic Kidney Disease (CKD)
    
    
                            Conditions: 
                                    
        
            
                        Chronic Kidney Disease (CKD)
                    
                                    
                
                                    Evaluation of Paclitaxel (Taxol, NSC #673089), Carboplatin (Paraplatin, NSC #241240), and BSI-201 (NSC #746045, IND #71,677) in the Treatment of Advanced, Persistent, or Recurrent Uterine Carcinosarcoma
                                
            
            
        Completed
                            
            
                To estimate the antitumor activity of paclitaxel, carboplatin, plus BSI-201 in patients with recurrent or advanced uterine carcinosarcomas.
Based on data generated by BiPar/Sanofi, it is concluded that iniparib does not possess characteristics typical of the PARP inhibitor class. The exact mechanism has not yet been fully elucidated, however based on experiments on tumor cells performed in the laboratory, iniparib is a novel investigational anti-cancer agent that induces gamma-H2AX (a marker of...  Read More             
        
        
    Gender:
                FEMALE
            Ages:
                18 years and above
            Trial Updated:
                08/01/2012
            
            Locations: Research Site, Chicago, Illinois  +3 locations         
        
        
            Conditions: Uterine Carcinosarcoma
        
            
        
    
                
                                    S9712: Radiation Therapy and Combination Chemotherapy in Treating Patients With Stage III Non-small Cell Lung Cancer
                                
            
            
        Completed
                            
            
                RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells. Combining more than one chemotherapy drug with radiation therapy may kill more tumor cells.
PURPOSE: Phase II trial to study the effectiveness of radiation therapy and chemotherapy consisting of carboplatin, etoposide and paclitaxel in treating patients with newly diagnosed stage III non-small cell lung cancer.             
        
        
    Gender:
                ALL
            Ages:
                18 years and above
            Trial Updated:
                07/20/2012
            
            Locations: Veterans Affairs Medical Center - Hines (Hines Junior VA Hospital), Hines, Illinois  +2 locations         
        
        
            Conditions: Lung Cancer
        
            
        
    
                
                                    Radiation Therapy, Chemotherapy, and Bevacizumab in Treating Patients With Recurrent, Unresectable or Stage III or Stage IV Non-Small Cell Lung Cancer
                                
            
            
        Terminated
                            
            
                RATIONALE: Radiation therapy uses high-energy x-rays to kill tumor cells. Drugs used in chemotherapy, such as paclitaxel and carboplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Monoclonal antibodies, such as bevacizumab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry tumor-killing substances to them. Bevacizumab...  Read More             
        
        
    Gender:
                ALL
            Ages:
                18 years and above
            Trial Updated:
                07/09/2012
            
            Locations: Robert H. Lurie Comprehensive Cancer Center at Northwestern University, Chicago, Illinois  +1 locations         
        
        
            Conditions: Lung Cancer
        
            
        
    
                
                                    Evaluation of Efficacy, Safety and Tolerability of Targretin Capsules in Patients With Advanced or Metastatic Non-small Cell Lung Cancer
                                
            
            
        Completed
                            
            
                This study evaluates the use of Targretin capsules (bexarotene) in combination with standard chemotherapy for the treatment of metastatic Non-Small Cell Lung Cancer (NSCLC) in patients who have not yet received chemotherapy for their lung cancer.             
        
        
    Gender:
                ALL
            Ages:
                All
            Trial Updated:
                07/07/2012
            
            Locations: Weiss Memorial Hospital, Chicago, Illinois  +4 locations         
        
        
            Conditions: Non-small Cell Lung Cancer
        
            
        
    
                
                                    Chemotherapy, Radiation Therapy, and Peripheral Stem Cell Transplantation in Treating Patients With Hodgkin's Disease
                                
            
            
        Completed
                            
            
                RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage cancer cells. Combining chemotherapy with peripheral stem cell transplantation may allow the doctor to give higher doses of chemotherapy drugs and kill more cancer cells.
PURPOSE: Phase II trial to study the effectiveness of chemotherapy, radiation therapy, and peripheral stem cell transplantation in treating patients who ha...  Read More             
        
        
    Gender:
                ALL
            Ages:
                65 years and below
            Trial Updated:
                06/21/2012
            
            Locations: Robert H. Lurie Comprehensive Cancer Center, Northwestern University, Chicago, Illinois         
        
        
            Conditions: Lymphoma
        
            
        
    
                
                                    S9720 Combination Chemotherapy in Treating Patients With Metastatic, Recurrent, or Refractory Endometrial Cancer
                                
            
            
        Completed
                            
            
                RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.
PURPOSE: Phase II trial to study the effectiveness of combination chemotherapy in treating patients with metastatic, recurrent, or refractory endometrial cancer.             
        
        
    Gender:
                FEMALE
            Ages:
                16 years and above
            Trial Updated:
                06/13/2012
            
            Locations: CCOP - Central Illinois, Decatur, Illinois  +2 locations         
        
        
            Conditions: Endometrial Cancer
        
            
        
    
                
                                    Chemotherapy, Filgrastim, and Stem Cell Transplantation With Radiation Therapy in Treating Patients With Stage III or Stage IV Breast Cancer
                                
            
            
        Completed
                            
            
                RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Colony-stimulating factors such as filgrastim may increase the number of immune cells found in bone marrow or peripheral blood and may help a person's immune system recover from the side effects of chemotherapy. Combining chemotherapy with autologous peripheral stem cell transplantation may allow the doctor to give higher doses of chemotherapy drugs and kill more tumor cells. R...  Read More             
        
        
    Gender:
                ALL
            Ages:
                65 years and below
            Trial Updated:
                06/08/2012
            
            Locations: Robert H. Lurie Comprehensive Cancer Center, Northwestern University, Chicago, Illinois         
        
        
            Conditions: Breast Cancer
        
            
        
    
                
                                    Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Stage III Non-small Cell Lung Cancer
                                
            
            
        Terminated
                            
            
                RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells. Combining chemotherapy and radiation therapy may kill more tumor cells.
PURPOSE: Phase I/II trial to study the effectiveness of combination chemotherapy plus radiation therapy in treating patients who have stage III non-small cell lung cancer.             
        
        
    Gender:
                ALL
            Ages:
                18 years and above
            Trial Updated:
                05/31/2012
            
            Locations: Robert H. Lurie Comprehensive Cancer Center, Northwestern University, Chicago, Illinois         
        
        
            Conditions: Lung Cancer
        
            
        
    
                
                                    Carboplatin Plus Vinorelbine in Treating Patients With Stage IIIB or Stage IV Non-small Cell Lung Cancer
                                
            
            
        Completed
                            
            
                RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.
PURPOSE: Phase I/II trial to study the effectiveness of combining carboplatin and vinorelbine in treating patients who have stage IIIB or stage IV non-small cell lung cancer.             
        
        
    Gender:
                ALL
            Ages:
                18 years and above
            Trial Updated:
                05/31/2012
            
            Locations: Robert H. Lurie Comprehensive Cancer Center, Northwestern University, Chicago, Illinois         
        
        
            Conditions: Lung Cancer
        
            
        
    
                
                                    TLK286 (Telcyta) in Combination With Carboplatin (Paraplatin) Versus Doxil in Platinum Refractory or Resistant Ovarian Cancer
                                
            
            
        Completed
                            
            
                The purpose of this research study is to determine if TLK286 given in combination with carboplatin is more effective than liposomal doxorubicin in treating women who have recurrent ovarian epithelial cancer, fallopian tube cancer, or primary peritoneal cancer, that is refractory or resistant to platinum chemotherapy.             
        
        
    Gender:
                FEMALE
            Ages:
                18 years and above
            Trial Updated:
                05/30/2012
            
            Locations: Joliet Oncology-Hematology Associates, Inc., Flossmoor, Illinois  +4 locations         
        
        
            Conditions: Ovarian Neoplasms
        
            
        
    
                
                                    Investigational Agent AG-013736 In Combinations With Standard Of Care Treatments For Patient's With Advanced Solid Tumor
                                
            
            
        Completed
                            
            
                To determine the best dose of this investigational agent AG-013736 in combination with various standard of care treatments for advanced solid tumors.             
        
        
    Gender:
                ALL
            Ages:
                18 years and above
            Trial Updated:
                03/30/2012
            
            Locations: Pfizer Investigational Site, Harvey, Illinois  +2 locations         
        
        
            Conditions: Neoplasms
        
            
        
    
                
                                    High-Dose Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Recurrent or Refractory Metastatic Breast Cancer
                                
            
            
        Completed
                            
            
                RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining chemotherapy with peripheral stem cell transplantation may allow the doctor to give higher doses of chemotherapy drugs and kill more tumor cells.
PURPOSE: Phase II trial to study the effectiveness of high-dose chemotherapy and peripheral stem cell transplantation in treating patients with recurrent or refractory metastatic breast cancer.             
        
        
    Gender:
                ALL
            Ages:
                Between 18 years and 65 years
            Trial Updated:
                02/19/2012
            
            Locations: University of Chicago Cancer Research Center, Chicago, Illinois  +1 locations         
        
        
            Conditions: Breast Cancer
        
            
        
    505 - 516 of 531
            